Request Demo

Last update 28 Jun 2025

Atezolizumab

Last update 28 Jun 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Anti-PDL-1-Genentech/Roche, Atezolizumab (Genetical Recombination), Atezolizumab (genetical recombination) (JAN)

+ [11]

Target

PDL1

Action

inhibitors

Mechanism

PDL1 inhibitors(Programmed death-ligand 1 inhibitors)

Therapeutic Areas

NeoplasmsDigestive System DisordersRespiratory Diseases+ [11]

Active Indication

Advanced Lung Non-Small Cell CarcinomaBreast CancerAlveolar Soft Part Sarcoma+ [172]

Inactive Indication

Acute Myeloid LeukemiaAdenocarcinoma of large intestineAdvanced Bile Duct Carcinoma+ [76]

Originator Organization

Genentech, Inc.Universitair Medisch Centrum Groningen

Active Organization

Hoffmann-La Roche, Inc.Roche Registration GmbH

Genentech, Inc.

+ [27]

Inactive Organization

Sanofi

Basilea Pharmaceutica AG

Roche Farma SA

+ [7]

License Organization

NeoImmuneTech, Inc.

Harpoon Therapeutics, Inc.Novocure, Inc.

+ [25]

Drug Highest PhaseApproved

First Approval Date

United States (18 May 2016),

Transitional Cell Carcinoma

RegulationBreakthrough Therapy (United States), Fast Track (United States), Accelerated Approval (United States), Orphan Drug (United States), Conditional marketing approval (China), Orphan Drug (Australia), Priority Review (Australia), Priority Review (China)

Structure/Sequence

Sequence Code 122091L

Source: *****

Sequence Code 4720027H

Source: *****

854

Clinical Trials associated with Atezolizumab

NCT07018947

/ Not yet recruitingPhase 2IIT

A Phase II, Randomized, Open-label, National, Multicenter Study Evaluating the Efficacy and Safety of the Combination of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in Hepatocellular Carcinoma (ASPIRE)

Study to evaluate the efficacy and safety of the combination of Atezolizumab and Bevacizumab as neoadjuvant plus adjuvant treatment in Hepatocellular Carcinoma.

Start Date01 Nov 2025

Sponsor / Collaborator-

NCT06066138

/ RecruitingPhase 1IIT

A Feasibility Multicenter Phase I Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Background:
A type of drug called monoclonal antibody immune checkpoint inhibitors are often used in cancer treatment. These drugs help the body s immune system fight cancer by blocking proteins that cause cancer cells to grow. One of these drugs (atezolizumab) is approved to treat certain cancers. Researchers want to find out if lower doses of this drug might provide the same benefit with fewer adverse effects.
Objective:
To test different doses and timing of atezolizumab for people with cancer.
Eligibility:
People aged 18 years and older with cancer that has spread locally or to other organs. They must be eligible for treatment with the study drug.
Design:
Participants will be screened. They will have blood tests and imaging scans. They will provide a sample of tissue from their tumor.
Atezolizumab is administered through a tube attached to a needle inserted into a vein in the arm. Participants will take this drug alone or combined with other drugs prescribed for their care.
The first 2 treatments will be done per the FDA recommended dose and schedule. Before administering the second dose of the study drug, researchers will check the level of the drug in the participant s blood. Depending on those results, their 3rd dose will be scheduled 2 to 6 weeks later.
For the 3rd dose of the study drug, participants will switch to the FDA minimum dosage. Dosages of any other drugs will not change.
Researchers will continue to test the levels of the drug in participants blood before each treatment for 16 weeks. After that, these levels will be tested every 3 months.
Study treatment may last up to 2 years.

Start Date01 Jul 2025

Sponsor / Collaborator

National Cancer Institute

NCT06603818

/ Not yet recruitingPhase 2IIT

A Phase II Study of Immunotherapies (Tiragolumab and Atezolizumab) in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)

Background:
Metastatic colorectal cancer (mCRC) is cancer that has spread beyond the colon and rectum. Most people with mCRC die within 5 years. New immune-based treatments are making progress with some types of colon cancer. But these treatments do little for people with a type of cancer that is microsatellite stable (MSS). MSS is a specific cancer biomarker. Better treatments are needed.
Objective:
To test 2 drugs (tiragolumab and atezolizumab) combined with radiation therapy in people with MSS mCRC.
Eligibility:
People aged 18 years and older with MSS mCRC.
Design:
Participants will be screened. They will have a physical exam with blood tests. They will have imaging scans and a test of their heart function. They will provide a tissue sample from their tumor; if one is not already available, a new sample will be taken. Their ability to perform normal tasks will be assessed.
Tiragolumab and atezolizumab are both administered through a tube attached to a needle inserted into a vein. Participants will receive both drugs on day 1 of 3-week treatment cycles. Each study visit should last about 8 hours.
Participants will receive radiation therapy on days 1, 3, and 5 of cycle 1 only.
Blood samples and rectal swabs will be collected on day 1 of every cycle.
Imaging scans will be repeated every 9 weeks. Additional tumor samples may be taken during treatment.
Treatment will continue for up to 2 years.
Participants will have a follow-up visit 1 month after treatment ends. Follow-up visits will continue every 3 months for 1 more year.

Start Date01 Jul 2025

Sponsor / Collaborator

National Cancer Institute

100 Clinical Results associated with Atezolizumab

100 Translational Medicine associated with Atezolizumab

100 Patents (Medical) associated with Atezolizumab

4,582

Literatures (Medical) associated with Atezolizumab

01 Dec 2025·CANCER CHEMOTHERAPY AND PHARMACOLOGY

Potential role of endothelial dysfunction in hypertension and proteinuria in patients with hepatocellular carcinoma receiving atezolizumab plus bevacizumab: a pilot prospective observational study

Article

Author: Kudo, Kenzo ; Nihei, Satoru ; Oikawa, Takayoshi ; Saito, Kazuki ; Ikeda, Tatsuki ; Asaka, Junichi ; Asahi, Koichi

PURPOSE:

Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF), is the first-line treatment for patients with unresectable hepatocellular carcinoma (HCC). Its inhibition of VEGF signaling may lead to proteinuria due to endothelial dysfunction but the association between endothelial function and clinical outcomes has not been established. This study aimed to investigate vascular endothelial function in patients with HCC receiving atezolizumab plus bevacizumab, and to assess the correlation between reactive hyperemia index (RHI) and adverse renal outcomes.

METHODS:

This pilot prospective observational study included 20 patients with HCC who received atezolizumab plus bevacizumab. We used reactive hyperemia-peripheral arterial tonometry (RH-PAT) and evaluated vascular endothelial function on the basis of RHI. RHI, blood pressure, and proteinuria were recorded at baseline and at 3 and 6 months after initiation of atezolizumab plus bevacizumab treatment. Statistical analyses were performed to investigate the relationship of RHI to blood pressure and proteinuria.

RESULTS:

Following initiation of atezolizumab plus bevacizumab treatment, systolic blood pressure and urine protein-creatinine ratio increased significantly, and RHI decreased. Patients with borderline or low baseline RHI had a higher incidence of grade ≥ 2 proteinuria than those with normal baseline RHI but not hypertension. A significant inverse correlation was found between RHI and urine protein-creatinine ratio.

CONCLUSION:

Bevacizumab administration may cause endothelial dysfunction in patients with HCC. The vascular endothelial function status before and during atezolizumab plus bevacizumab treatment is associated with the risk of bevacizumab-induced proteinuria.

01 Sep 2025·CHEMOSPHERE

Optimizing the atrazine degradation in g-C3N4@BiOBr/polyvinylidene fluoride photocatalytic membrane system

Article

Author: Gar Alalm, Mohamed ; Fuoad, Mohram ; Samy, Mahmoud ; Hamdy, Nourhan ; El-Geundi, Mohammad

In this study, g-C₃N₄@BiOBr heterostructure was synthesized at different molar ratios and dispersed into a polyvinylidene fluoride (PVDF) matrix for the photodegradation of atrazine (ATZ, herbicide) under visible light. The investigation of the photocatalytic performance of g-C₃N₄@BiOBr/PVDF membrane under different operating parameters has not been extensively studied in the literature. Thus, this study focused on the optimization of the g-C₃N₄@BiOBr/PVDF membrane degradation system and deep exploration of the degradation mechanism. Various analyses characterized the as-prepared catalysts and membranes, including XRD, TEM, FTIR, EDX, SEM, XPS, and DRS. The g-C₃N₄@BiOBr/PVDF membrane (g-C₃N₄@BiOBr at a mole ratio 1:3) showed the highest photocatalytic activity for ATZ removal among the composite membranes. The response surface methodology (RSM) was used to optimize the operating parameters, exhibiting that pH 3, initial ATZ concentration of 0.5 mg/L, and BiOBr mole ratio of 0.75 were the optimum conditions. The contribution of reactive species to the degradation mechanism was investigated using efficient scavengers, confirming the significant roles of •O₂^- and h⁺ in the reaction process. Furthermore, the as-prepared membrane demonstrated enhanced reusability and stability with an 81 % ATZ removal rate after five cycles. The generated intermediates were identified using liquid chromatography-mass spectroscopy analysis indicating the degradation of ATZ to simpler compounds. The mechanism of the photocatalytic degradation of atrazine by g-C₃N₄@BiOBr/PVDF was further proposed. This study proposes a low-cost, efficient, and stable photocatalytic membrane system that can be executed in real applications.

01 Sep 2025·JOURNAL OF HAZARDOUS MATERIALS

Transformation of Atrazine on δ-MnO2 surfaces under dry conditions: Hydrolysis and dealkylation

Article

Author: Zhou, Jinjin ; Gao, Juan ; Sun, Zhaoyue ; Wang, Xinghao

Atrazine (ATZ) is a frequently detected herbicide in corn fields, and manganese oxides (MnO₂) are reactive soil components. Reportedly, the sole use of MnO₂ cannot efficiently achieve ATZ removal in aqueous solution. However, this study found that 90.2 % of ATZ could be degraded on δ-MnO₂ surfaces under dry conditions (mineral moisture content < 3 %, relative humidity (RH) ≤ 97.30 %). Atrazine-desisopropyl-2-hydroxy and 2-hydroxyatrazine were obtained as the main products through the dealkylation and hydrolysis of ATZ, and the intermediates exhibited low ecotoxicity toward aquatic organisms. The experiments were conducted at 23°C (RH: 6.40-97.3 %). Based on quenching experiments, Mn(IV) contributed approximately 88.0 % to ATZ degradation by accepting electrons from Cl and N in ATZ, forming Mn-Cl-C and Mn-N-H bonds, and reducing the activation energy required for hydrolysis based on DFT calculation. The oxygen vacancy in δ-MnO₂ provided no considerable contribution to ATZ removal. RH notably influenced the processes, and the optimal RH value was 22.5 %. Similar mechanisms were observed for simazine, simetone, propazine, and ametryn on δ-MnO₂ surfaces. In agricultural soil featuring low Mn contents, ATZ degradation was limited (< 1.0 %), however, the ATZ transformation efficiency increased to 31.2 % and 63.0 % after the addition of 1 % and 5 % δ-MnO₂ particles. The effectiveness of δ-MnO₂ was significantly correlated with the soil texture (R = 0.81-0.91, p < 0.05). These findings provide insights into the abiotic degradation mechanisms of triazine herbicides in dry soils, presenting strategies to remove triazine herbicide residues from soil.

1,411

News (Medical) associated with Atezolizumab

24 Jun 2025

·www.prnewswire.com

Accord Healthcare receives approval for Hetronifly® (Serplulimab), from the Medicines and Healthcare Regulatory Agency (MHRA) for first-line treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Intas and its subsidiary Accord Healthcare lead commercialisation in Europe and India. In December 2022, serplulimab received orphan drug designation from the EC for the treatment of SCLC, this was recently reviewed by the committee and renewed. ESMO has scored serplulimab 4 out of 5 on their magnitude of clinical benefit scale (MCBS) in ES-SCLC. Serplulimab is the only anti-PD-1 mAb approved for the first-line treatment of ES-SCLC and has now reached over 110,000 patients. It has been approved in nearly 40 countries, including China, Europe, India and multiple Southeast Asian countries. LONDON, June 24, 2025 /PRNewswire/ -- Accord Healthcare Limited (Accord) is delighted to announce that the anti-PD-1 mAb, serplulimab, marketed as Hetronifly®, has been approved by the MHRA to treat adults in the UK with extensive-stage small cell lung cancer (ES-SCLC), which has not previously been treated and has spread within the lungs or to other parts of the body. This approval comes in the same week as the announcement in India, bringing the total number of countries and regions in which the medicine is approved to over 40 — including Europe, China, Indonesia, and Singapore. Accord Healthcare will lead commercialisation in both the UK and India on behalf of its parent company, Intas, and its commercial partner, Henlius. Lung cancer remains the leading cause of cancer-related death globally. Small cell lung cancer (SCLC), one of the most aggressive subtypes, accounts for approximately 15% of all lung cancer cases and is associated with limited treatment options[1]. Julian Beach, Interim Executive Director of Healthcare Quality and Access at the UK's Medicines and Healthcare products Regulatory Agency (MHRA), commented: "As the first and only anti-PD-1 monoclonal antibody approved in the UK for small cell lung cancer, this marks an important new treatment option for patients with this aggressive type of lung cancer who currently have limited choices and face a poor prognosis."[2] Henlius Biotech originally developed Serplulimab. In 2023, Henlius entered into a collaboration with Intas Pharmaceuticals, granting Intas exclusive rights to develop and commercialise the medicine in over 50 countries across Europe and India. Welcoming the news, Paul Tredwell, Executive Vice-President EMENA, Accord Healthcare, said: "At Accord, we are dedicated to supporting patients with cancer. The MHRA's approval of Hetronifly® provides a new treatment option in the fight against extensive-stage small cell lung cancer — one of the most aggressive forms of lung cancer. This milestone reflects our ongoing commitment to providing novel specialty medicines for difficult-to-treat conditions." Ping Cao, Chief Business Development Officer and Senior Vice President of Henlius said: "The approvals of serplulimab in the UK and India not only represent continued progress in our globalisation strategy but also reflect our concrete commitment to putting patients first. We are steadily expanding the global reach of the product, aiming to bring high-quality innovative therapies to more patients around the world." In December 2022, serplulimab received orphan drug designation from the EC for the treatment of SCLC, this was recently reviewed by the committee and renewed. ESMO has also scored serplulimab 4 out of 5 on their magnitude of clinical benefit scale (MCBS) in ES-SCLC. About Serplulimab Serplulimab (recombinant humanised anti-PD-1 monoclonal antibody injection)) is an anti-PD-1 mAb for the first-line treatment of SCLC and has been approved in China and several SEA countries. Serplulimab has been approved by the National Medicinal Products Administration (NMPA) in China for the treatment of squamous non-small cell lung cancer (sqNSCLC), extensive-stage small cell lung cancer (ES-SCLC), esophageal squamous cell carcinoma (ESCC) and non-squamous non-small cell lung cancer (nsNSCLC). Serplulimab was granted orphan drug designations by the FDA and the EC for the treatment of SCLC, and its bridging head-to-head trial in the United States to compare serplulimab to standard of care atezolizumab (anti-PD-L1 mAb) for the first-line treatment of ES-SCLC is well under way. The results of 4 pivotal trials of serplulimab were published in the Journal of the American Medical Association (JAMA), Nature Medicine, Cancer Cell and British Journal of Cancer, respectively. Furthermore, serplulimab was respectively recommended by the CSCO Guidelines for Small Cell Lung Cancer, the CSCO Guidelines for Non-Small Cell Lung Cancer, the CSCO Guidelines for Esophageal Cancer, the CSCO Clinical Practice Guidelines on Immune Checkpoint Inhibitor, the China Guidelines for Radiotherapy of Esophageal Cancer, and other definitive guides, providing valuable references for clinical diagnosis and treatment of tumours. The approvals were primarily based on the results of the global phase 3 clinical study ASTRUM-005, which enrolled 585 patients across 128 trial sites worldwide. At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, the results from the final analysis of ASTRUM-005 were presented, showing a median follow-up of 42.4 months and a 4-year overall survival (OS) rate of 21.9% (95% CI: 17.6–26.6%) for the serplulimab plus chemotherapy group. These results further confirm the long-term survival benefit of this immunotherapy-based regimen for patients with ES-SCLC. About Lung Cancer Lung cancer is the most common cancer worldwide in terms of incidence and mortality. According to GLOBOCAN 2022, there were over 2.48 million new cases of lung cancer globally in 2022, accounting for 12.4% of all new cancer cases.[1] Small cell lung cancer (SCLC), which accounts for 15% to 20% of all lung cancers, is characterised by high malignancy, early metastasis, rapid progression, and poor prognosis. Among SCLC patients, approximately 30% to 40% are diagnosed at a limited stage, while the remaining cases are in an extensive stage. Within Europe, the prevalence of SCLC ranges from 1 to 5 per 10,000 people.[3] References Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263. doi:10.3322/caac.21834 MHRA approves the UK's first anti-PD-1 monoclonal antibody for the treatment of an aggressive form of lung cancer. last accessed June 2025 Dingemans AC, Früh M, Ardizzoni A, et al. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆. Ann Oncol. 2021;32(7):839-853. doi:10.1016/j.annonc.2021.03.207 Logo - WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Drug ApprovalClinical ResultASCOImmunotherapyOrphan Drug

23 Jun 2025

·www.fiercebiotech.com

Exelixis\' blockbuster hopeful beats Bayer drug in pivotal cancer trial, sending stock higher

Investors sent Exelixis’ share price up 12% to about $45 on Monday.\n A combination featuring Exelixis’ experimental drug zanzalintinib has beaten Bayer’s gastrointestinal cancer med Stivarga in a phase 3 trial. The overall survival win moves Exelixis a step closer to its ambition of turning the oral tyrosine kinase inhibitor into a $5 billion-a-year product.Exelixis is developing zanzalintinib as the successor to its flagship oncology medicine Cabometyx. By improving attributes including pharmacokinetic half-life, the company has designed a molecule that it believes can win approval in a range of diseases and blast past Cabometyx’s peak sales. The phase 3 colorectal cancer trial was a key early proving ground for zanzalintinib.Investigators randomized 901 patients to receive Stivarga or zanzalintinib in combination with Roche’s checkpoint inhibitor Tecentriq. Overall survival in previously treated non-microsatellite instability-high metastatic colorectal cancer was significantly longer on the combination than on Stivarga.William Blair analysts said in a note to investors that the hit on the trial’s co-primary endpoint ensures a “meaningful commercial opportunity for the budding franchise.” The patient population covered by the endpoint represents the largest commercial opportunity open to zanzalintinib, according to analysts, who estimated risk-adjusted U.S. peak sales of $875 million. The analysts will be looking out for relative and absolute risk reduction when the full results are shared, because “these metrics could help us ascertain the clinical meaningfulness of the survival benefit.” But the available results are positive, leading investors to send Exelixis’ share price up 12% to about $45 on Monday.Exelixis will, however, need to rack up more clinical wins to deliver its major vision for zanzalintinib. The biotech expects GI cancers, including colorectal tumors, to account for 45% of the $5 billion in sales it hopes to generate in 2033. GI cancers accounted for 10% of Cabometyx sales last year, making the indications central to Exelixis’ ambitions to improve on the $1.8 billion generated by its current product.The biotech’s pursuit of the phase 3 colorectal cancer population could put it in competition with drugs including Amgen’s Lumakras, Bayer’s Stivarga, Taiho Oncology’s Lonsurf and Takeda’s Fruzaqla.

$Exelixis\' blockbuster hopeful beats Bayer drug in pivotal cancer trial, sending stock higher$

Phase 3Clinical ResultADC

23 Jun 2025

·pipelinereview.com

Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer

– Zanzalintinib in combination with atezolizumab demonstrated a statistically significant reduction in risk of death versus regorafenib in intent-to-treat population – ALAMEDA, CA, USA I June 22, 2025 I Exelixis, Inc. (Nasdaq: EXEL) today announced positive topline results from the STELLAR-303 phase 3 pivotal trial in which zanzalintinib in combination with atezolizumab (Tecentriq ® ) demonstrated a statistically significant improvement in overall survival (OS) versus regorafenib in the intent-to-treat (ITT) population of patients with previously treated non-microsatellite instability (MSI)-high metastatic colorectal cancer (CRC). These topline findings are from the final analysis conducted by the Independent Data Monitoring Committee of one of the dual primary endpoints of the STELLAR-303 phase 3 trial. The trial will proceed to the planned final analysis for the other dual primary endpoint of OS in patients without liver metastases (non-liver metastases, NLM). The safety profiles of zanzalintinib in combination with atezolizumab and of regorafenib were generally consistent with what has been previously observed, and no new safety signals were identified. The ITT population consisted of all randomized patients, regardless of the presence of liver metastases. The NLM subgroup consisted of patients who did not have active liver metastases at baseline as determined by investigator assessment. “The STELLAR-303 results, which showed a survival benefit with the combination of zanzalintinib and atezolizumab versus regorafenib across all randomized patients with previously treated metastatic colorectal cancer, marks an important first milestone for our zanzalintinib pivotal development program,” said Amy Peterson, M.D., Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer, Exelixis. “We look forward to discussing the findings with regulatory authorities and presenting the detailed results at an upcoming medical conference.” Secondary endpoints of STELLAR-303 include progression-free survival, objective response rate and duration of response in the ITT population and in the NLM subgroup of patients. Exelixis plans to submit detailed results of STELLAR-303 for presentation at an upcoming medical conference. About STELLAR-303 STELLAR-303 (NCT05425940) is a global, multicenter, randomized, phase 3, open-label study that randomized 901 patients 1:1 to either zanzalintinib (100 mg) in combination with atezolizumab or regorafenib. The study includes patients with previously treated non-MSI-high metastatic CRC. The dual primary endpoints of the study are OS in the ITT population and in the NLM subgroup of patients. Presence of liver metastases at baseline for all enrolled patients was determined by investigator assessment. Secondary endpoints include progression-free survival, objective response rate and duration of response in the ITT population and in the NLM subgroup of patients. More information about the trial is available at ClinicalTrials.gov . About Zanzalintinib Zanzalintinib is a third-generation oral tyrosine kinase inhibitor that inhibits the activity of receptor tyrosine kinases implicated in cancer growth and spread, including VEGF receptors, MET, AXL and MER. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumor angiogenesis and resistance to multiple therapies, including immune checkpoint inhibitors. With zanzalintinib, Exelixis sought to build upon its extensive experience with the target profile of cabozantinib, the company’s flagship medicine, while improving key characteristics, including pharmacokinetic half-life. Zanzalintinib is currently being developed for the treatment of advanced solid tumors, including colorectal cancer, kidney cancer, head and neck cancer and neuroendocrine tumors. Zanzalintinib is an investigational agent that is not approved for any use and is the subject of ongoing clinical trials. About CRC CRC is the third most common cancer and the second leading cause of cancer-related deaths in the U.S. 1 Approximately 154,000 new cases will be diagnosed in the U.S. with around 53,000 expected deaths from the disease in 2025. 1 CRC is most frequently diagnosed among people aged 65-74 and is more common in men and in people of non-Hispanic American Indian/Alaska Native descent. 2 Nearly a quarter of CRC cases are diagnosed at the metastatic stage, at which point the five-year survival rate is just 16.2%. 2 The liver is the most common site for CRC metastasis. Liver metastases significantly impact survival, with a median five-year survival rate of less than 14% when treated with palliative chemotherapy. 3 About Exelixis Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX ® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit www.exelixis.com , follow @ExelixisInc on X (Twitter), like Exelixis, Inc. on Facebook and follow Exelixis on LinkedIn. 1 Key Statistics for Colorectal Cancer. ACS website. Available at: https://www.cancer.org/cancer/types/colon-rectal-cancer/about/key-statistics.html . Accessed June 2025. 2 Cancer Stat Facts: Colorectal Cancer. SEER website. Available at: https://seer.cancer.gov/statfacts/html/colorect.html . Accessed June 2025. 3 Ros J, Salva F, Dopazo C, et al. Liver transplantation in metastatic colorectal cancer: are we ready for it? Br J Cancer. May 2023;128(10):1797-1806. SOURCE: Exelixis

Clinical ResultPhase 3

100 Deals associated with Atezolizumab

External Link

KEGG	Wiki	ATC	Drug Bank
D10773	Atezolizumab	L01XC32	DB11595

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Advanced Lung Non-Small Cell Carcinoma	European Union	Roche Registration GmbH	25 Jul 2024
Advanced Lung Non-Small Cell Carcinoma	Iceland	Roche Registration GmbH	25 Jul 2024
Advanced Lung Non-Small Cell Carcinoma	Liechtenstein	Roche Registration GmbH	25 Jul 2024
Advanced Lung Non-Small Cell Carcinoma	Norway	Roche Registration GmbH	25 Jul 2024
Breast Cancer	Canada	F. Hoffmann-La Roche Ltd.	13 Mar 2024
Alveolar Soft Part Sarcoma	United States	Genentech, Inc.	09 Dec 2022
PD-L1 positive Non-Small Cell Lung Cancer	Japan	Chugai Pharmaceutical Co., Ltd.	26 May 2022
BRAF V600 mutation-positive Melanoma	United States	Genentech, Inc.	30 Jul 2020
PD-L1 positive Triple Negative Breast Cancer	Japan	Chugai Pharmaceutical Co., Ltd.	19 Jan 2018
Advanced Hepatocellular Carcinoma	European Union	Roche Registration GmbH	20 Sep 2017
Advanced Hepatocellular Carcinoma	Iceland	Roche Registration GmbH	20 Sep 2017
Advanced Hepatocellular Carcinoma	Liechtenstein	Roche Registration GmbH	20 Sep 2017
Advanced Hepatocellular Carcinoma	Norway	Roche Registration GmbH	20 Sep 2017
Advanced Triple-Negative Breast Carcinoma	European Union	Roche Registration GmbH	20 Sep 2017
Advanced Triple-Negative Breast Carcinoma	Iceland	Roche Registration GmbH	20 Sep 2017
Advanced Triple-Negative Breast Carcinoma	Liechtenstein	Roche Registration GmbH	20 Sep 2017
Advanced Triple-Negative Breast Carcinoma	Norway	Roche Registration GmbH	20 Sep 2017
Extensive stage Small Cell Lung Cancer	European Union	Roche Registration GmbH	20 Sep 2017
Extensive stage Small Cell Lung Cancer	Iceland	Roche Registration GmbH	20 Sep 2017
Extensive stage Small Cell Lung Cancer	Liechtenstein	Roche Registration GmbH	20 Sep 2017

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Extranodal NK-T-Cell Lymphoma	NDA/BLA	Japan	Chugai Pharmaceutical Co., Ltd.	31 Oct 2024
Diabetes Mellitus, Type 1	NDA/BLA	China	Provention Bio, Inc.	28 Aug 2024
Bladder Cancer	NDA/BLA	China	Roche Holding AG	25 Feb 2019
Lymphoproliferative Disorders	Phase 3	United Kingdom	-	25 Oct 2023
Melanoma	Phase 3	United Kingdom	-	25 Oct 2023
Microsatellite instability-high cancer	Phase 3	United Kingdom	-	25 Oct 2023
Turcot Syndrome	Phase 3	United Kingdom	-	25 Oct 2023
Muscle Invasive Bladder Carcinoma	Phase 3	Belgium	Hoffmann-La Roche, Inc.	03 May 2021
Muscle Invasive Bladder Carcinoma	Phase 3	Hong Kong	Hoffmann-La Roche, Inc.	03 May 2021
Muscle Invasive Bladder Carcinoma	Phase 3	Mexico	Hoffmann-La Roche, Inc.	03 May 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03811002 (NRG-LU005, CTgov)	Phase 3	Small cell lung cancer limited stage	544	Intensity-Modulated Radiation Therapy+Etoposide+Carboplatin+cisplatin (Arm I (Chemotherapy, Radiation Therapy))	edaidgabqe(eavjevoykz) = bsxziypiei plovmulomj (akfwzkycdd, klxwcglruu - eqkdiovmkc) View more	-	12 Jun 2025
				Intensity-Modulated Radiation Therapy+Etoposide+Carboplatin+cisplatin+Atezolizumab (Arm II (Chemotherapy, Radiation Therapy, Atezolizumab))	edaidgabqe(eavjevoykz) = ernsowmxgx plovmulomj (akfwzkycdd, jqslnevrzv - qtaonbmcmc) View more
NCT03197935 (IMpassion031, Pubmed \| Nat Med)	Phase 3	Triple Negative Breast Cancer Neoadjuvant ctDNA-positive	-	Peri-operative Atezolizumab	zqfioyztie(ikdmexorjn): HR = 0.76 (95% CI, 0.44 - 1.3) View more	Positive	04 Jun 2025
				Preoperative Placebo
NCT04408118 (ATRACTIB, Pubmed \| Nat Med)	Phase 2	Advanced Triple-Negative Breast Carcinoma First line	-	Atezolizumab + Paclitaxel + Bevacizumab	nwmstavnwk(xgqnjluyfp) = rvrqhglmhh nnwdmrakkb (ejabixfwxr, 52.8 - 72.4) View more	Positive	04 Jun 2025
NCT05091567 (IMforte, ASCO2025) Manual	Phase 3	Extensive stage Small Cell Lung Cancer Maintenance \| First line	660	Lurbinectedin + Atezolizumab	jpbmehcduk(yschmgpmsx) = bxqwxlnden xpmamczuyu (upjrmvksud, 4.2 - 5.8) View more	Positive	30 May 2025
				Atezolizumab	jpbmehcduk(yschmgpmsx) = mpwdbexgeu xpmamczuyu (upjrmvksud, 1.6 - 2.7) View more
NCT02912559 (Alliance A021502; ATOMIC, ASCO2025) Manual	Phase 3	Mismatch repair-deficient Colonic Cancer Adjuvant Deficient DNA Mismatch Repair (dMMR)	712	atezolizumab + mFOLFOX6	dcvmntpyuj(jccbrlntlm) = nnkrnnjhou genjaqzzfy (qijuijfxwt, 81.8 - 89.9) View more	Positive	30 May 2025
				mFOLFOX6	dcvmntpyuj(jccbrlntlm) = wdxcizpgxy genjaqzzfy (qijuijfxwt, 71.3 - 81.0) View more
ASCO2025	Not Applicable	Hepatocellular Carcinoma INR \| platelet count	-	Atezolizumab/Bevacizumab	yvvhmrywsm(fsoxtaeisa) = uqducbmcjn selxmdtijm (ocovpenhfh ) View more	-	30 May 2025
				Durvalumab/Tremelimumab	yvvhmrywsm(fsoxtaeisa) = ykagcqvtrd selxmdtijm (ocovpenhfh ) View more
ASCO2025	Not Applicable	Unresectable Hepatocellular Carcinoma	75	atezolizumab (Sarcopenia)	trurobfuof(ycpdrelblh) = dlxcewfeyt nfxmejzlno (yxiwwbqskt ) View more	Negative	30 May 2025
				atezolizumab (Non-sarcopenia)	trurobfuof(ycpdrelblh) = bsvtlkgkee nfxmejzlno (yxiwwbqskt ) View more
NCT04440735 (Phase 2 dose expansion study of DSP107, ASCO2025)	Phase 2	Metastatic Microsatellite Stable Colorectal Carcinoma Third line CD47	50	DSP107 monotherapy	vqltzypkge(lfblyykjfs) = 10% Grade 1 or 2 beqogcmorv (zzyzkclfcl ) View more	Positive	30 May 2025
				DSP107 + Atezolizumab
NCT05109442 (Phase 1/2a study, ASCO2025)	Phase 2	Advanced Malignant Solid Neoplasm	28	AFM24 + Atezolizumab	omejzjjcrm(pefoatdrpn) = lrjzgimuwy ailsnbheot (rqoqgfdcmc ) View more	Positive	30 May 2025
NCT03614949 (ASCO2025)	Phase 2	Metastatic Carcinoma to the Uterine Cervix Maintenance PD-L1+	21	Atezolizumab	jsvrafnfpc(uirvdxuyfz) = dsjbnnjbfb flbacgzttt (xslkpefnck, 7.6 - 54) View more	Positive	30 May 2025

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis